Vireo Growth Inc Stock Price, News & Analysis

Vireo Growth has completed its acquisition of Proper Brands in Missouri through its subsidiaries NGH Investments and Proper Holdings Management. The deal, valued at $102.0 million, was paid entirely in Vireo stock with 196.2 million Subordinate Voting Shares at $0.52 per share. Proper Brands, established in 2022, operates 11 retail dispensaries primarily in St. Louis, with one location in Kansas City and an additional undeveloped license. The company features a 100,000+ square foot cultivation and manufacturing facility and is implementing the Arches technology platform for home delivery. The purchase price represents 4.175x Proper's 2024 Closing EBITDA of $31 million. The deal includes clawback provisions tied to 2026 EBITDA performance and share lock-up provisions spanning 33 months.

Vireo Growth Inc. (VREOF) has successfully closed two strategic acquisitions: WholesomeCo Cannabis, a dominant player in Utah's medical market, and the Arches proprietary technology platform for a total of $69.8 million. The deal was executed through 134.2 million Subordinate Voting Shares at $0.52 per share.

The Wholesome acquisition, valued at 4.175x its 2024 Reference EBITDA of $16 million, includes clawback provisions tied to performance milestones through December 2026. Shareholders agreed to a 33-month lock-up period. The company also expects to close pending mergers in Missouri and Nevada in Q2 2025.

Vireo Growth reported its Q1 2025 financial results with revenue of $24.5 million, up 1.9% year-over-year. The company posted gross profit of $12.4 million with a margin of 50.6%, while Adjusted EBITDA reached $6.6 million with a margin of 26.8%. Operating income declined 58.5% to $2.0 million. The company maintained strong liquidity with $86.3 million in cash and total current assets of $128.5 million. Vireo experienced growth in Maryland, stable performance in Minnesota, and declining medical sales in New York, offset by new adult-use sales. The company expects to begin closing its pending merger transactions in Q2 2025, including Utah transactions with Wholesome Cannabis and the Arches technology platform.

Vireo Growth has scheduled the release of its first quarter 2025 financial results for May 9, 2025, before market opening. The cannabis company, trading under symbols CSE: VREO and OTCQX: VREOF, will follow the release with an investor conference call at 8:30 a.m. ET (7:30 a.m. CT).

Stakeholders can participate in the conference call through multiple channels:

• US/Canada Toll-Free: 1-888-672-2415
• International Toll: 1-646-307-1963
• Conference ID: 3718174

Additionally, interested parties can access a live audio webcast through the Events & Presentations section of Vireo's Investor Relations website or via the provided Q4 link.

Vireo Growth (CSE: VREO; OTCQX: VREOF) has announced key updates regarding its previously-announced Merger Transactions, expected to close in Q2 2025. The company has filed its Definitive Information Circular on March 21, 2025, which includes proforma financial information for the combined company and audited financial data for 2023-2024 for all merger targets.

The company has secured required shareholder approval through written consent for the Merger Transactions and the issuance of Subordinate Voting Shares (SV Shares) as consideration. The issuance is significant as it will exceed 100% of the company's total outstanding voting equity shares.

Regulatory approvals have been obtained for the Utah transactions, including Wholesome Cannabis and the Arches technology platform. The Missouri and Nevada transactions are progressing as planned for Q2 2025 closure, pending CSE approval and satisfaction of customary closing conditions.

Vireo Growth (VREOF) reported strong financial results for Q4 and full year 2024, achieving record performance metrics. FY2024 revenue reached $99.4 million, marking a 15.4% year-over-year increase excluding discontinued operations. Q4 2024 revenue was $25.0 million, up 3.5% year-over-year but flat sequentially.

The company ended FY2024 with $91.6 million in cash following a successful private placement in December, where investors subscribed for 129,536,874 shares at $0.625 per share, raising approximately $81 million. Q4 results included one-time transaction expenses of $4.2 million related to pending merger transactions.

Additionally, Vireo secured two significant loans through its Minnesota subsidiary: a $11.5 million facility at 10.5% interest for a new indoor cultivation facility, and a $15.0 million commercial loan from Stearns Bank at 9.25% interest.

Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) has announced it will release its fourth quarter and full year 2024 financial results on March 4, 2025, before market opening. The company will host a conference call with investors on the same day at 8:30 a.m. ET (7:30 a.m. CT). Interested parties can join via phone using toll-free number 1-800-715-9871 (US and Canada) or 1-646-307-1963 (International) with conference ID 3718174. A live audio webcast will be available through the company's Investor Relations website.

Vireo Growth has successfully closed an oversubscribed private placement offering, raising US$81 million through the issuance of 129,536,874 Subordinate Voting Shares at US$0.625 per share. The offering price represents a 16.8% premium to the closing share price on OTCQX as of December 27, 2024.

The company plans to utilize the net proceeds for business development, including organic and acquisitive growth investments, working capital, and general corporate purposes. The offering, initially planned for US$75 million, exceeded expectations with oversubscribed demand. Lineage Merchant Partners acted as placement agent, with securities placed through GT Securities.

Vireo Growth Inc. has announced a major expansion through a $75 million equity financing at $0.625 per share and acquisitions of four single-state cannabis operators for approximately $397 million in all-stock transactions. The acquisitions include Proper Brands (Missouri), Deep Roots Harvest (Nevada), WholesomeCo Cannabis (Utah), and The Flowery (Florida).

The combined entity will operate across 7 states with 9 cultivation facilities and 48 dispensaries. The company projects 2024 proforma revenue of $394 million and EBITDA of $94 million. The transactions include the proprietary Arches technology platform for cannabis delivery and analytics.

John Mazarakis has been appointed CEO and Co-Executive Chairman, while Tyson Macdonald becomes CFO. The combined company will have approximately $99 million in cash and $78 million in net debt, with an EBITDA leverage ratio of 0.8x.